Affiliation:
1. Department of Pharmacy, Faculty of Life and Earth Sciences, Jagannath University, Dhaka, Bangladesh
Abstract
Abstract:
Potassium-competitive acid blockers (P-CABs), such as tegoprazan, are a new and diverse
class of drugs that can completely block the potassium-binding site of gastric H+/K+
ATPase, potentially overcoming the limitations of proton-pump inhibitors (PPIs). A number of
studies have compared the effectiveness as well as the safety profile of tegoprazan to PPIs and
other P-CABs for the treatment of gastrointestinal diseases. The current review study evaluates the
published works of literature related to clinical pharmacology and clinical trials of tegoprazan for
the treatment of diseases related to the gastrointestinal tract. According to the publications included
in the study, tegoprazan was found to be safe and well-tolerated and can be used to treat a
group of gastrointestinal diseases, including gastroesophageal reflux disease (GERD), non-erosive
reflux disease (NERD), and H. pylori combination therapy.
Publisher
Bentham Science Publishers Ltd.
Subject
Psychiatry and Mental health